The US Food and Drug Administration (FDA) approved a long-acting multiple sclerosis drug from Biogen, of Cambridge, Massachusetts, and AbbVie, of North Chicago, Illinois, to treat relapsing forms of the disease. The agency gave the self-administered under-the-skin injection Zinbryta (daclizumab) the go-ahead in May, basing its decision on data from two trials, including one showing fewer relapses compared with placebo. Zinbryta is an antibody that binds the interleukin-2 receptor CD25 on T cells, inhibiting the proliferation of activated T cells and their involvement in autoimmunity and the immune responses that can follow organ transplantation. The drug originated from Protein Design Lab (now PDL BioPharma), which had pursued a collaboration with Roche resulting in the 1997 approval of the antibody for kidney transplant rejection. In 2005,PDL and Biogen Idec partnered to develop the antibody for use in multiple sclerosis, and in 2008, PDL spun off its biotech operations into Facet Biotech, of Redwood City, California. Then in 2010, Abbott outbid Biogen to acquire Facet for approximately $450 million (Nat. Biotechnol. 28, 387–389, 2010). Although the once-a-month injection offers another option to patients who have failed multiple treatments, Zinbryta's safety and tolerability issues resulted a boxed warning. Some analysts predict that this label could hamper its market potential by relegating use to a smaller patient population. Biogen's MS pipeline took a knock in June when anti-Lingo-1 monoclonal antibody opicinumab missed its primary and secondary endpoints in phase 2 studies.